We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Reta, Melese Abate![]() |
|
dc.contributor.author | Tamene, Birhan Alemnew![]() |
|
dc.contributor.author | Abate, Biruk Beletew![]() |
|
dc.contributor.author | Mensah, Eric![]() |
|
dc.contributor.author | Maningi, Nontuthuko Excellent![]() |
|
dc.contributor.author | Fourie, Petrus Bernard![]() |
|
dc.date.accessioned | 2023-10-24T09:44:19Z | |
dc.date.available | 2023-10-24T09:44:19Z | |
dc.date.issued | 2022-10-14 | |
dc.description | SUPPLEMENTARY MATERIALS : FIGURES S1A–E; FIGURES S2A–D; FIGURES S3A–D; FIGURES S4A–D; FIGURES S5A–D; FIGURES S6A–E; FIGURES S7A–D; FIGURES S8A–D. TABLE S1: PRISMA- 2020-checklist; TABLE S2: Search Strategy Medline/PubMed; TABLE S3: Quality assessments. | en_US |
dc.description | DATA AVAILABILITY STATEMENT : The datasets analyzed during this review can be accessed from the corresponding author upon reasonable request. | en_US |
dc.description.abstract | BACKGROUND : Tuberculosis (TB) remains a significant global public health issue, despite advances in diagnostic technologies, substantial global efforts, and the availability of effective chemotherapies. Mycobacterium tuberculosis, a species of pathogenic bacteria resistant to currently available anti-TB drugs, is on the rise, threatening national and international TB-control efforts. This systematic review and meta-analysis aims to estimate the pooled prevalence of drug-resistant TB (DR-TB) in Ethiopia. MATERIALS AND METHODS : A systematic literature search was undertaken using PubMed/MEDLINE, HINARI, theWeb of Science, ScienceDirect electronic databases, and Google Scholar (1 January 2011 to 30 November 2020). After cleaning and sorting the records, the data were analyzed using STATA 11. The study outcomes revealed the weighted pooled prevalence of any anti-tuberculosis drug resistance, any isoniazid (INH) and rifampicin (RIF) resistance, monoresistance to INH and RIF, and multidrug-resistant TB (MDR-TB) in newly diagnosed and previously treated patients with TB. RESULTS : A total of 24 studies with 18,908 patients with TB were included in the final analysis. The weighted pooled prevalence of any anti-TB drug resistance was 14.25% (95% confidence interval (CI): 7.05–21.44%)), whereas the pooled prevalence of any INH and RIF resistance was found in 15.62% (95%CI: 6.77–24.47%) and 9.75% (95%CI: 4.69–14.82%) of patients with TB, respectively. The pooled prevalence for INH and RIF-monoresistance was 6.23% (95%CI: 4.44–8.02%) and 2.33% (95%CI: 1.00–3.66%), respectively. MDR-TB was detected in 2.64% (95%CI: 1.46–3.82%) of newly diagnosed cases and 11.54% (95%CI: 2.12–20.96%) of retreated patients with TB, while the overall pooled prevalence of MDR-TB was 10.78% (95%CI: 4.74–16.83%). CONCLUSIONS : In Ethiopia, anti-tuberculosis drug resistance is widespread. The estimated pooled prevalence of INH and RIF-monoresistance rates were significantly higher in this review than in previous reports. Moreover, MDR-TB in newly diagnosed cases remained strong. Thus, early detection of TB cases, drug-resistance testing, proper and timely treatment, and diligent follow-up of TB patients all contribute to the improvement of DR-TB management and prevention. Besides this, we urge that a robust, routine laboratory-based drug-resistance surveillance system be implemented in the country. | en_US |
dc.description.department | Medical Microbiology | en_US |
dc.description.librarian | am2023 | en_US |
dc.description.uri | https://www.mdpi.com/journal/tropicalmed | en_US |
dc.identifier.citation | Reta, M.A.; Tamene, B.A.; Abate, B.B.;Mensah, E.;Maningi, N.E.; Fourie, P.B. Mycobacterium tuberculosis Drug Resistance in Ethiopia: An Updated Systematic Review and Meta-Analysis. Tropical Medicine and Infectious Disease 2022, 7, 300. https://DOI.org/10.3390/tropicalmed7100300. | en_US |
dc.identifier.issn | 2414-6366 (online) | |
dc.identifier.other | 10.3390/tropicalmed7100300 | |
dc.identifier.uri | http://hdl.handle.net/2263/93025 | |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.rights | © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_US |
dc.subject | MDR-TB | en_US |
dc.subject | Meta-analysis | en_US |
dc.subject | Ethiopia | en_US |
dc.subject | Mycobacterium tuberculosis (MTB) | en_US |
dc.subject | Drug-resistant tuberculosis (DRTB) | en_US |
dc.subject | Tuberculosis (TB) | en_US |
dc.title | Mycobacterium tuberculosis drug resistance in Ethiopia : an updated systematic review and meta-analysis | en_US |
dc.type | Article | en_US |